COMMUNIQUÉS West-GlobeNewswire

Radical™ Catheter Technologies Announces U.S. FDA 510(k) Clearance for its 6F Neurovascular Catheter -- Broadening Access Across a Wide Range of Applications
13/04/2026
Radical Catheter Technologies Continues to Expand its Best-in-Class Patented Platform and Scale its Specialized Neurovascular Commercialization Team LOS GATOS, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Radical™ [...]
IBA – ACQUISITION D’ACTIONS PROPRES
13/04/2026
Louvain-la-Neuve, Belgique, 13 avril 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
Sienna for Seniors Foundation $1 Million Gift Advances Healthy Aging Research at Ontario Tech University
13/04/2026
Contribution will support work exploring older adult well-being, happiness, engagement and connection Pictured (left to right): John Henry, Regional Chair, Durham Region; Nitin Jain, President and CEO, Sienna Senior [...]
IBA – ACQUISITION OF OWN SHARES
13/04/2026
Louvain-la-Neuve, Belgium, April 13 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
13/04/2026
Déclaration de transactions sur actions propres Paris, France (13 avril 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 7 avril 2026, les [...]
Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Rica’s Coyol Free Trade Zone
13/04/2026
BROOKLYN PARK, MN, April 13, 2026 (GLOBE NEWSWIRE) -- Switchback Medical, a medical device contract development and manufacturing organization (CDMO), announced it has signed a lease for a new 18,000-square-foot [...]
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
13/04/2026
Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ® ) and bevacizumab was tolerable, with no new safety signals in patients with advanced [...]
BiomX Accelerates Defense Technology Buildout with DFSL Acquisition
13/04/2026
Acquisition expands BiomX’s defense portfolio with aligned capabilities designed to integrate across detection, analysis, and response, reinforcing its position in AI-enabled security systems NETANYA, Israel, April 13, [...]
EmPRO Reports Another Year of Strong Financial Results with Significant Growth in Net Income and Surplus During 2025
13/04/2026
ROSLYN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- EmPRO Insurance Company (EmPRO), a licensed medical professional liability insurance carrier serving physicians and healthcare facilities, today announced strong [...]
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
13/04/2026
Analysis demonstrates D-PLEX₁₀₀ prolonged delivery mechanism ability to deliver continuous release of doxycycline for 30 days at the surgical incision site PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- [...]
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
13/04/2026
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
SafeSpace Global Corporation Announces Operational Expansion to Support Commercial Deployment of its AI-safety platform and Growing Revenue Activities
13/04/2026
KNOXVILLE, TN., April 13, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation ("SafeSpace" or the "Company") (OTCID: SSGC), a leader in multimodal AI-powered safety and security solutions, dedicated to safety [...]
Xealth to Facilitate Critical Discussion Among Health System Executives on How to Maximize Digital Health Value at Becker’s Annual Meeting
13/04/2026
CHICAGO, April 13, 2026 (GLOBE NEWSWIRE) -- Becker’s 16 th Annual Meeting -- Xealth , the leading care orchestration platform for digital health, today announced that Xealth Strategic Medical Advisor and Samsung [...]
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
13/04/2026
Policy Update Broadens Access to Innovative, Non-Drug Depression Treatment Across 26 States and Washington, D.C. MALVERN, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology [...]
Vireo Growth Announces California Retail Joint Venture with Glass House Brands
13/04/2026
MINNEAPOLIS and LONG BEACH, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Glass House Brands Inc. (“Glass House”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: [...]
Glass House Brands Announces California Retail Joint Venture with Vireo Growth
13/04/2026
LONG BEACH, Calif. and TORONTO, April 13, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF) and Vireo Growth Inc. ("Vireo") (CSE: [...]
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
13/04/2026
Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need SARASOTA, Fla., April [...]
Free Oral Cancer Screenings in Honor of Oral, Head and Neck Cancer Awareness Month
13/04/2026
49 USOSM Surgeon Partners to Participate Across 14 States IRVING, Texas, April 13, 2026 (GLOBE NEWSWIRE) -- In honor of Oral, Head and Neck Cancer Awareness Month, 49 U.S. Oral Surgery Management (USOSM) surgeon [...]
Neomorph Announces Closing of $100 Million Series B Financing
13/04/2026
Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement of the company’s [...]

Pages